1. Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest.
    Yang WS, Stockwell BR.
    Genome Biol. 2008;9(6):R92. Epub 2008 Jun 2. | Pubmed
  2. Does GATA3 act in tissue-specific pathways? A meta-analysis-based approach.
    Wilson BJ.
    J Carcinog. 2008;7:6.| Pubmed
  3. Molecular and prognostic markers in prostate cancer - A study of cell-cycle regulators, angiogenesis and candidate markers - Introduction.
    Halvorsen, OJ
    APMIS Suppl. 2008;(123):5-62.| Pubmed
  4. Arylamine N-acetyltransferases: From structure to function.
    Sim, E; Walters, K; Boukouvala, S
    Drug Metab Rev. 2008;40(3):479-510.| Pubmed
  5. MMSET is overexpressed in cancers: Link with tumor aggressiveness.
    Kassambara A, Klein B, Moreaux J.
    Biochem Biophys Res Commun. 2008 Dec 30. [Epub ahead of print]| Pubmed
  6. Transcriptome and proteome analyses of drug interactions with natural products.
    Fang H, Wang K, Zhang J.
    Curr Drug Metab. 2008 Dec;9(10):1038-48. | Pubmed
  7. Confirmation of Gene Expression - Based Prediction of Survival in Non-Small Cell Lung Cancer.
    Guo, NL; Wan, YW; Tosun, K; Lin, H; Msiska, Z; Flynn, DC; Remick, SC; Vallyathan, V; Dowlati, A; Shi, X; Castranova, V; Beer, DG; Qian, Y
    Clin Cancer Res. 2008 Dec 15;14(24):8213-20.| Pubmed
  8. A stem cell gene expression profile of human squamous cell carcinomas.
    Jensen KB, Jones J, Watt FM.
    Cancer Lett. 2008 Dec 8;272(1):23-31. Epub 2008 Jul 26. | Pubmed
  9. Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma.
    Tshuikina, M; Jernberg-Wiklund, H; Nilsson, K; Oberg, F
    Exp Hematol. 2008 Dec;36(12):1673-1681. Epub 2008 Oct 15.| Pubmed
  10. Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4.
    Murn J, Alibert O, Wu N, Tendil S, Gidrol X.
    J Exp Med. 2008 Dec 22;205(13):3091-103. Epub 2008 Dec 15.| Pubmed
  11. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
    Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, Zielenska M, Soares FA, Squire JA.
    Mod Pathol. 2008 Dec;21(12):1451-60. Epub 2008 May 23. | Pubmed
  12. Modulation of Runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer.
    Khalid O, Baniwal SK, Purcell DJ, Leclerc N, Gabet Y, Stallcup MR, Coetzee GA, Frenkel B.
    Endocrinology. 2008 Dec;149(12):5984-95. Epub 2008 Aug 28. | Pubmed
  13. A functional Notch-survivin gene signature in basal breast cancer.
    Lee CW, Simin K, Liu Q, Plescia J, Guha M, Khan A, Hsieh CC, Altieri DC.
    Breast Cancer Res. 2008;10(6):R97. Epub 2008 Nov 24.| Pubmed
  14. Tissue Inhibitor of Metalloproteinases-4. The road less traveled.
    Melendez-Zajgla, J; Del Pozo, L; Ceballos, G; Maldonado, V
    Mol Cancer. 2008 Nov 21;7:85.| Pubmed
  15. Identifying differential correlation in gene/pathway combinations.
    Braun, R; Cope, L; Parmigiani, G
    BMC Bioinformatics. 2008 Nov 18;9:488.| Pubmed
  16. The Fbxw7/hCdc4 tumor suppressor in human cancer.
    Tan Y, Sangfelt O, Spruck C.
    Cancer Lett. 2008 Nov 18;271(1):1-12. Epub 2008 Jun 9. | Pubmed
  17. The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1-Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer.
    Arnoldussen, YJ; Lorenzo, PI; Pretorius, ME; Waehre, H; Risberg, B; Maelandsmo, GM; Danielsen, HE; Saatcioglu, F
    Cancer Res. 2008 Nov 15;68(22):9255-64.| Pubmed
  18. Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation.
    Perotti C, Liu R, Parusel CT, Böcher N, Schultz J, Bork P, Pfitzner E, Groner B, Shemanko CS.
    Breast Cancer Res. 2008;10(6):R94. Epub 2008 Nov 13.| Pubmed
  19. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer.
    Yang Y, Iyer LK, Adelstein SJ, Kassis AI.
    PLoS ONE. 2008;3(11):e3661. Epub 2008 Nov 6.| Pubmed
  20. DNA Hypomethylation Arises Later in Prostate Cancer Progression than CpG Island Hypermethylation and Contributes to Metastatic Tumor Heterogeneity.
    Yegnasubramanian, S; Haffner, MC; Zhang, YG; Gurel, B; Cornish, TC; Wu, ZJ; Irizarry, RA; Morgan, J; Hicks, J; DeWeese, TL; Isaacs, WB; Bova, GS; De Marzo, AM; Nelson, WG
    Cancer Res. 2008 Nov 1;68(21):8954-67.| Pubmed
  21. A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene.
    Gobeil S, Zhu X, Doillon CJ, Green MR.
    Genes Dev. 2008 Nov 1;22(21):2932-40. | Pubmed
  22. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.
    Engelsen, IB; Stefansson, IM; Akslen, LA; Salvesen, HB
    Am J Obstet Gynecol. 2008 Nov;199(5):543.e1-7. Epub 2008 Jul 3.| Pubmed
  23. Systematic identification and validation of candidate genes for detection of circulating tumor cells in peripheral blood specimens of colorectal cancer patients.
    Findeisen, P; Rockel, M; Nees, M; Roder, C; Kienle, P; Doeberitz, MV; Kalthoff, H; Neumaier, M
    Int J Oncol. 2008 Nov;33(5):1001-10.| Pubmed
  24. Notch1 is an effector of Akt and hypoxia in melanoma development.
    Bedogni, B; Warneke, JA; Nickoloff, BJ; Giaccia, AJ; Powell, MB
    J Clin Invest. 2008 Nov;118(11):3660-70. Epub 2008 Oct 16.| Pubmed
  25. Golgi Protein GOLM1 Is a Tissue and Urine Biomarker of Prostate Cancer.
    Varambally, S; Laxman, B; Mehra, R; Cao, Q; Dhanasekaran, S; Tomlins, SA; Granger, J; Vellaichamy, A; Sreekumar, A; Yu, JJ; Gu, WJ; Shen, RL; Ghosh, D; Wright, LM; Kladney, RD; Kuefer, R; Rubin, MA; Fimmel, CJ; Chinnaiyan, AM
    Neoplasia. 2008 Nov;10(11):1285-94.| Pubmed
  26. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.
    Van Laere S, Beissbarth T, Van der Auwera I, Van den Eynden G, Trinh XB, Elst H, Van Hummelen P, van Dam P, Van Marck E, Vermeulen P, Dirix L.
    Clin Cancer Res. 2008 Nov 15;14(22):7452-60.| Pubmed
  27. The network biomarker discovery in prostate cancer from both genomics and proteomics levels.
    Jin GX, Zhou XB, Cui KM, et al.
    Conference Information: 2nd International Symposium on Optimization and Systems Biology, OCT 31-NOV 03, 2008 Lijiang, PEOPLES R CHINASource: OPTIMIZATION AND SYSTEMS BIOLOGY, PROCEEDINGS Book Series: Lecture Notes in Operations Research Volume: 9 Pages: 144-151 Published: 2008
  28. FYN is overexpressed in human prostate cancer.
    Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta KJ, Stadler WM, Rinker-Schaeffer C, Salgia R.
    BJU Int. 2008 Oct 16. [Epub ahead of print]| Pubmed
  29. The Polarity Protein Par6 Induces Cell Proliferation and Is Overexpressed in Breast Cancer.
    Nolan, ME; Aranda, V; Lee, S; Lakshmi, B; Basu, S; Allred, DC; Muthuswamy, SK
    Cancer Res. 2008 Oct 15;68(20):8201-9.| Pubmed
  30. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.
    Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJ, Cardiff RD, Carraway KL 3rd, Sweeney C.
    Cancer Res. 2008 Oct 15;68(20):8286-94. | Pubmed
  31. The correlation between cellular size and protein expression levels - Normalization for global protein profiling.
    Lundberg, E; Gry, M; Oksvold, P; Kononen, J; Andersson-Svahn, H; Ponten, F; Uhlen, M; Asplund, A
    J Proteomics. 2008 Oct 7;71(4):448-60. Epub 2008 Jul 5.| Pubmed
  32. Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell tumorigenesis.
    Kang, YK; Schiff, R; Ko, L; Wang, T; Tsai, SY; Tsai, MJ; O’Malley, BW
    Cancer Res. 2008 Oct 1;68(19):7887-96.| Pubmed
  33. Proteomic profiling of the effect of prostate-specific antigen on prostate cancer cells.
    Bindukumar B, Schwartz S, Aalinkeel R, Mahajan S, Lieberman A, Chadha K.
    Prostate. 2008 Oct 1;68(14):1531-45. | Pubmed
  34. Copper & biological health.
    Krupanidhi S, Sreekumar A, Sanjeevi CB.
    Indian J Med Res. 2008 Oct;128(4):448-61. | Pubmed
  35. A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma.
    Chaerkady R, Harsha HC, Nalli A, Gucek M, Vivekanandan P, Akhtar J, Cole RN, Simmers J, Schulick RD, Singh S, Torbenson M, Pandey A, Thuluvath PJ.
    J Proteome Res. 2008 Oct;7(10):4289-98. Epub 2008 Aug 21. | Pubmed
  36. Acid sphingomyelinase overexpression enhances the antineoplastic effects of irradiation in vitro and in vivo.
    Smith, EL; Schuchman, EH
    Br J Cancer. 2008 Sep 16;99(6):939-48.| Pubmed
  37. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.
    Kristiansen, G; Fritzsche, FR; Wassermann, K; Jager, C; Toelle, A; Lein, M; Stephan, C; Jung, K; Pilarsky, C; Dietel, M; Moch, H
    Br J Cancer. 2008 Sep 16;99(6):939-48.| Pubmed
  38. Akt regulation and lung cancer: a novel role and mechanism of action for the tumor suppressor Par-4.
    Diaz-Meco MT, Moscat J.
    Cell Cycle. 2008 Sep 15;7(18):2817-20. Epub 2008 Sep 5. | Pubmed
  39. Key Issues in Conducting a Meta-Analysis of Gene Expression Microarray Datasets.
    Ramasamy, A; Mondry, A; Holmes, CC; Altman, DG
    PLoS Med. 2008 Sep 2;5(9):e184. [Epub ahead of print]| Pubmed
  40. Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer.
    Woods Ignatoski KM, Grewal NK, Markwart SM, Vellaichamy A, Chinnaiyan AM, Yeung K, Ray ME, Keller ET.
    Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):153-60. | Pubmed
  41. Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment.
    Lange K, Kammerer M, Saupe F, Hegi ME, Grotegut S, Fluri E, Orend G.
    Cancer Res. 2008 Sep 1;68(17):6942-52. | Pubmed
  42. Studying chromosome instability in the mouse.
    Foijer, F; Draviam, VM; Sorger, PK
    Biochim Biophys Acta. 2008 Sep;1786(1):73-82. Epub 2008 Jul 26.| Pubmed
  43. RCS1, a substrate of APC/C, controls the metaphase to anaphase transition.
    Zhao, WM; Coppinger, JA; Seki, A; Cheng, XL; Yates, JR; Fang, GW
    Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13415-20. Epub 2008 Aug 29.| Pubmed
  44. Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.
    Tseng-Rogenski SS, Arredouani MS, Neeley YC, Lu B, Chinnaiyan AM, Sanda MG.
    Cancer Immunol Immunother. 2008, Sep;57(9):1357-65. Epub 2008 Feb 12.| Pubmed
  45. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.
    Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM.
    Mod Pathol. 2008 Sep;21(9):1156-67. Epub 2008 Jun 20. | Pubmed
  46. GATA-3 as a Marker of Hormone Response in Breast Cancer.
    Fang SH, Chen Y, Weigel RJ.
    J Surg Res. 2008 Aug 26. [Epub ahead of print]| Pubmed
  47. Wilms’ tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
    Han, YQ; Yang, L; Suarez-Saiz, F; San-Marina, S; Cui, J; Minden, MD
    Mol Cancer Res. 2008 Aug;6(8):1347-55.| Pubmed
  48. Membrane-associated phospholipase A1 beta (LIPI) is an Ewing tumour-associated cancer/testis antigen.
    Foell, JL; Hesse, M; Volkmer, I; Schmiedel, BJ; Neumann, I; Staege, MS
    Pediatr Blood Cancer. 2008 Aug;51(2):228-34.| Pubmed
  49. Meta-analysis of SUMO1.
    Wilson BJ.
    BMC Res Notes. 2008 Jul 31;1:60.| Pubmed
  50. ATF6 alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo.
    Schewe, DM; Aguirre-Ghiso, JA
    Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10519-24. Epub 2008 Jul 23.| Pubmed
  51. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis.
    Frohlich, DA; McCabe, MT; Arnold, RS; Day, ML
    Oncogene. 2008 Jul 17;27(31):4353-62. Epub 2008 Mar 31.| Pubmed
  52. Acetylcholinesterase supports anchorage independence in colon cancer.
    Syed, M; Fenoglio-Preiser, C; Skau, KA; Weber, GF
    Clin Exp Metastasis. 2008;25(7):787-98. Epub 2008 Jul 9.| Pubmed
  53. Recurrent gene fusions in prostate cancer.
    Kumar-Sinha C, Tomlins SA, Chinnaiyan AM.
    Nat Rev Cancer. 2008 Jul;8(7):497-511. Epub 2008 Jun 19.| Pubmed
  54. Pathway analysis reveals functional convergence of gene expression profiles in breast cancer.
    Shen R, Chinnaiyan AM, Ghosh D.
    BMC Med Genomics. 2008 Jun 27;1:28. | Pubmed
  55. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer.
    Grady WM, Parkin RK, Mitchell PS, Lee JH, Kim YH, Tsuchiya KD, Washington MK, Paraskeva C, Willson JK, Kaz AM, Kroh EM, Allen A, Fritz BR, Markowitz SD, Tewari M.
    Oncogene. 2008 Jun 19;27(27):3880-8. Epub 2008 Feb 11. | Pubmed
  56. Targeting the BAF57 SWI/SNF subunit in prostate cancer: A novel platform to control androgen receptor activity.
    Link, KA; Balasubramaniam, S; Sharma, A; Comstock, CES; Godoy-Tundidor, S; Powers, N; Cao, KH; Haelens, A; Claessens, F; Revelo, MP; Knudsen, KE
    Cancer Res. 2008 Jun 15;68(12):4551-8.| Pubmed
  57. Genomic outlier profile analysis: mixture models, null hypotheses, and nonparametric estimation.
    Ghosh D, Chinnaiyan AM.
    Biostatistics. 2008 Jun 6.| Pubmed
  58. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway.
    Wilson BJ, Giguère V.
    Mol Cancer. 2008 Jun 4;7:49.| Pubmed
  59. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene.
    Ganesan, K; Ivanova, T; Wu, YH; Rajasegaran, V; Wu, J; Lee, MH; Yu, K; Rha, SY; Chung, HC; Ylstra, B; Meijer, G; Lian, KO; Grabsch, H; Tan, P
    Cancer Res. 2008 Jun 1;68(11):4277-86.| Pubmed
  60. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis.
    Chan, TA; Glockner, S; Yi, JM; Chen, W; Van Neste, L; Cope, L; Herman, JG; Velculescu, V; Schuebel, KE; Ahuja, N; Baylin, SB
    PLoS Med. 2008 May 27;5(5):e114.| Pubmed
  61. Re: Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
    Lusa, L; Peissel, B; Manoukian, S; Marchesi, E; Radice, P; Pierotti, MA; Gariboldi, M
    J Natl Cancer Inst. 2008 May 21;100(10):752-3; author reply 753-4. Epub 2008 May 13.| Pubmed
  62. A constitutional translocation t(1;17)(p36.2;q11.2) in a neuroblastoma patient disrupts the human NBPF1 and ACCN1 genes.
    Vandepoele K, Andries V, Van Roy N, Staes K, Vandesompele J, Laureys G, De Smet E, Berx G, Speleman F, van Roy F.
    PLoS One. 2008 May 21;3(5):e2207. | Pubmed
  63. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
    Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM.
    Cancer Res. 2008 May 15;68(10):3584-90.| Pubmed
  64. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer.
    Meyer, KB; Maia, AT; O’Reilly, M; Teschendorff, AE; Chin, SF; Caldas, C; Ponder, BAJ
    PLoS Biol. 2008 May 6;6(5):e108.| Pubmed
  65. The discovery and application of gene fusions in prostate cancer.
    Morris DS, Tomlins SA, Montie JE, Chinnaiyan AM.
    BJU Int. 2008 Apr 16.| Pubmed
  66. Elevated tRNA(i)(Met) synthesis can drive cell proliferation and oncogenic transformation.
    Marshall, L; Kenneth, NS; White, RJ
    Cell. 2008 Apr 4;133(1):78-89.| Pubmed
  67. Amplification and overexpression of PPFIAI, a putative IIq13 invasion suppressor gene, in head and neck squamous cell carcinoma.
    Tan, KD; Zhu, Y; Tan, HK; Rajasegaran, V; Aggarwal, A; Wu, J; Wu, HY; Hwang, J; Lim, DTH; Soo, KC; Tan, P
    Genes Chromosomes Cancer. 2008 Apr;47(4):353-62.| Pubmed
  68. Opportunities posed by novel patient selection biomarker approaches in oncology drug development: going beyond the cytotoxics.
    Grant Sellar, John D Alvarez, Frank Loganzo, Richat Abbas, Fred Immermann, Maha Karnoub, Giora Z Feuerstein, Michael E Burczynski, Christina M Coughlin
    Biomarkers in Medicine, April 2008, Vol. 2, No. 2, Pages 147-153 | Link
  69. The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome.
    Butt, AJ; Sergio, CM; Inman, CK; Anderson, LR; McNeil, CM; Russell, AJ; Nousch, M; Preiss, T; Biankin, AV; Sutherland, RL; Musgrove, EA
    Breast Cancer Res. 2008;10(2):R28. Epub 2008 Mar 29.| Pubmed
  70. Predicting cancer involvement of genes from heterogeneous data.
    Aragues, R; Sander, C; Oliva, B
    BMC Bioinformatics. 2008 Mar 27;9:172.| Pubmed
  71. TM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expression.
    Zhou, Z; Ran, YL; Hu, H; Pan, J; Li, ZF; Chen, LZ; Sun, LC; Peng, L; Zhao, XL; Yu, L; Sun, LX; Yang, ZH
    Clin Exp Metastasis. 2008;25(5):537-48. Epub 2008 Mar 26.| Pubmed
  72. Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer.
    McCabe, CD; Spyropoulos, DD; Martin, D; Moreno, CS
    Cancer Res. 2008 Mar 15;68(6):1988-96.| Pubmed
  73. Tumor cell dependence on Ran-GTP-directed mitosis.
    Xia, F; Lee, CW; Altieri, DC
    Cancer Res. 2008 Mar 15;68(6):1826-33.| Pubmed
  74. Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates.
    Li, RS; Guo, Y; Han, BM; Yan, XW; Utleg, AG; Li, W; Tu, LC; Wang, J; Hood, L; Xia, SJ; Lin, BY
    Proteomics. 2008 Mar 7;2(4):543-555
  75. p73 poses a barrier to malignant transformation by limiting anchorage-independent growth.
    Beitzinger, M; Hofmann, L; Oswald, C; Beinoraviciute-Kellner, R; Sauer, M; Griesmann, H; Bretz, AC; Burek, C; Rosenwald, A; Stiewe, T
    EMBO J. 2008 Mar 5;27(5):792-803. Epub 2008 Jan 31.| Pubmed
  76. Gene expression profiling of non-small-cell lung cancer.
    Lacroix, L; Commo, F; Soria, JC
    Expert Rev Mol Diagn. 2008 Mar;8(2):167-78.| Pubmed
  77. CXCL5 promotes prostate cancer progression.
    Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM, Macoska JA.
    Neoplasia. 2008 Mar;10(3):244-54.| Pubmed
  78. Humoral response profiling reveals pathways to prostate cancer progression.
    Taylor BS, Pal M, Yu J, Laxman B, Kalyana-Sundaram S, Zhao R, Menon A, Wei JT, Nesvizhskii AI, Ghosh D, Omenn GS, Lubman DM, Chinnaiyan AM, Sreekumar A.
    Mol Cell Proteomics. 2008 Mar;7(3):600-11. Epub 2007 Dec 11.< | Pubmed
  79. Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers.
    Chan SK, Griffith OL, Tai IT, Jones SJ.
    Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):543-52. | Pubmed
  80. Hsp60 regulation of tumor cell apoptosis.
    Ghosh, JC; Dohi, T; Kang, BH; Altieri, DC
    J Biol Chem. 2008 Feb 22;283(8):5188-94. Epub 2007 Dec 17.| Pubmed
  81. Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1.
    Guan B, Pungaliya P, Li X, Uquillas C, Mutton LN, Rubin EH, Bieberich CJ.
    J Biol Chem. 2008 Feb 22;283(8):4834-40. Epub 2007 Dec 12. | Pubmed
  82. Phosphorylation of Skp2 regulated by CDK2 and Cdc14B protects it from degradation by APC(Cdh1) in G1 phase.
    Rodier G, Coulombe P, Tanguay PL, Boutonnet C, Meloche S.
    EMBO J. 2008 Feb 20;27(4):679-91. Epub 2008 Jan 31. | Pubmed
  83. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
    Sorensen, KD; Borre, M; Orntoft, TF; Dyrskjot, L; Torring, N
    Int J Cancer. 2008 Feb 1;122(3):509-19.| Pubmed
  84. Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways.
    Ruiz-Vela, A; Aggarwal, M; de la Cueva, P; Treda, C; Herreros, B; Martfn-Perez, D; Dominguez, O; Piris, MA
    Blood. 2008 Feb 1;111(3):1665-76. Epub 2007 Nov 21.| Pubmed
  85. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.
    Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA, Chinnaiyan AM.
    Cancer Res. 2008 Feb 1;68(3):645-9.| Pubmed
  86. CD200: a putative therapeutic target in cancer.
    Moreaux J, Veyrune JL, Reme T, De Vos J, Klein B.
    Biochem Biophys Res Commun. 2008 Feb 1;366(1):117-22. Epub 2007 Dec 4.| Pubmed
  87. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression.
    Gordon, KJ; Dong, M; Chislock, EM; Fields, TA; Blobe, GC
    Carcinogenesis. 2008 Feb;29(2):252-62. Epub 2007 Nov 13.| Pubmed
  88. CLEAR-test: Combining inference for differential expression and variability in microarray data analysis.
    Valls, J; Grau, M; Sole, X; Hernandez, P; Montaner, D; Dopazo, J; Peinado, MA; Capella, G; Moreno, V; Pujana, MA
    J Biomed Inform. 2008 Feb;41(1):33-45. Epub 2007 May 17.| Pubmed
  89. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
    Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM.
    Neoplasia. 2008 Feb;10(2):177-88.| Pubmed
  90. Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation.
    Smith DD, Saetrom P, Snove O Jr, Lundberg C, Rivas GE, Glackin C, Larson GP.
    BMC Bioinformatics. 2008 Jan 28;9(1):63| Pubmed
  91. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
    Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R, Chinnaiyan AM.
    Cancer Res. 2008 Jan 1;68(1):73-80.| Pubmed
  92. A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival.
    Chinnaiyan, AM; Lippman, ME; Yu, JJ; Yu, J; Cordero, KE; Johnson, MD; Ghosh, D; Rae, JM
    Neoplasia. 2008 Jan;10(1):79-88.| Pubmed
  93. Pathway analysis tools and toxicogenomics reference databases for risk assessment.
    Ganter B, Zidek N, Hewitt PR, Müller D, Vladimirova A.
    Pharmacogenomics. 2008 Jan;9(1):35-54. | Pubmed
  94. DLG1 is an anchor for the E3 ligase MARCH2 at sites of cell-cell contact.
    Cao, ZF; Huett, A; Kuballa, P; Giallourakis, C; Xavier, RJ
    Cell Signal. 2008 Jan;20(1):73-82. Epub 2007 Sep 12.| Pubmed
  95. Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer.
    Wong, SY; Crowley, D; Bronson, RT; Hynes, RO
    Clin Exp Metastasis. 2008;25(2):109-18. Epub 2007 Dec 5.| Pubmed